This request for proposals is open to projects that focus on therapy optimization in pediatric blood cancers that aim to minimize both short- and long-term treatment-associated toxicities.
Traditional treatments for pediatric blood cancer often include chemotherapy, radiation and stem cell transplant which can have significant short-term and long-term consequences on the developing body of a child. There is a critical unmet need to reduce the burden of toxicity caused by the current standard of care while maintaining efficacy.
Research Topic
This RFP welcomes clinical trials focused on therapy optimization in all types of pediatric blood cancers, such as new combination therapy, reduction of chemotherapy by integrating immunotherapy, and reduction in intensity or duration of maintenance therapy.
We encourage interventional clinical trials (Phase I, II, or III) that include measurements of biomarkers to drive treatment decision-making and to assess the impact of an intervention (e.g., minimal residual disease). This should help to correlate optimization or de-escalation of treatment while maintaining efficacy.
Additionally, interventional clinical trials that focus on novel, less-toxic, targeted agents and immunotherapies, which might improve outcomes and decrease toxicity compared to current regimens, will also be considered.
Clinical Trial Eligibility Criteria
Clinical trials are eligible if they meet all the following criteria:
- Phase I, Phase II, or Phase III clinical trials
- Interventional clinical trials with the potential to address unmet patient needs, such as improving/maintaining disease control while reducing side effects and improving quality of life during therapy
- Serve patients’ interests with primary endpoints that seek to demonstrate clinical benefit
- Include symptom quantification or functional improvement or decline measurements selected with patient input (HRQOL or PRO)
- Patient-centric: Applicants must include a patient involvement plan (as defined below) that includes patient partners throughout the clinical trial conception, planning, and implementation
Basic research, translational studies, and research involving animals are NOT eligible for application.
Awards
The amount allocated per grant will depend on the number of applications selected for funding. The duration of an award is usually up to five years. Please be aware that RTFCCR usually covers 30% of the total trial costs, therefore co-funding is requested.
How to apply
1) Letter of Intent phase – 29 August to 22 November 2024
We receive Letter of Intent (LOIs) through our online grant management platform SmartSimple (SmartSimple | Rising Tide Foundation). LOIs will be assessed by internal staff and advisory board members. The most promising LOIs aligning with this request for proposal topics will be invited to submit a full grant application.
Additional supportive documentation: CVs, clinical trial protocols and charts showing estimated accrual overtime can be uploaded separately to SmartSimple.